BeyondSpring Presents Final Data Analysis from DUBLIN-3 Phase 3 Trial in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 Page 1

The combination of plinabulin/docetaxel showed a favorable benefit/risk ratio compared to docetaxel alone: ​​significant improvement in overall survival, progression-free survival and objective response, with an additional significant reduction in grade 4 neutropenia (>80% relative reduction) and improved quality of life of patients

FLORHAM PARK, NJ, September 16, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, presented final data from the Dublin-3 trial (2L/3L EGFR wild-type NSCLC) with a focus on safety outcomes on September 14, 2024 at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, ​​Spain. The full data from the Dublin-3 trial were published in the Lancet Respiratory Medicine on September 9, 2024 (https://doi.org/10.1016/S2213-2600(24)00178-4).